Adaptimmune Therapeutics PLC (ADAP)

[jondoeuk]

The company and Noile-Immune have announce an agreement to develop SPEAR T-cell products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients https://www.globenewswire.com/news-release/2019/08/27/1907041/0/en/Adaptimmune-and-Noile-Immune-Announce-Agreement-to-Develop-SPEAR-T-Cell-Products-expressing-IL-7-and-CCL19-as-a-next-generation-treatment-for-cancer-patients.html

From the PR Karen Miller, ADAP's SVP of Pipeline Research states: ''This agreement with Noile-Immune will enable us to generate next-generation SPEAR T-cells secreting both IL-7 and CCL19*, which may improve proliferation and trafficking of not only our engineered SPEAR T-cells, but also the patient’s own T-cells into solid tumors. This increased T-cell proliferation and trafficking may enhance anti-tumor activity for cancer patients.''

* Here is some preclinical data https://www.nature.com/articles/nbt.4086